Targeting CPSF73, the mRNA 3' End Processing Endonuclease, Moves Cancer Cells Away from the Mesenchymal State

This study demonstrates that inhibiting the mRNA 3' end processing endonuclease CPSF73 induces widespread 3'UTR lengthening via alternative polyadenylation, which reverses the epithelial-mesenchymal transition (EMT) and suppresses metastasis in multiple cancer cell lines, highlighting APA modulation as a promising therapeutic strategy.

The Gist

The Big Picture: Stopping the Cancer "Chameleon"

Imagine cancer cells as chameleons. To spread (metastasize) from one part of the body to another, they have to change their "skin." They start as stiff, stationary cells (like bricks in a wall) and transform into slippery, mobile cells (like jellyfish) that can swim through the bloodstream to new locations. This transformation is called the Epithelial-Mesenchymal Transition (EMT).

Once these cells turn into "jellyfish," they are very hard to catch and kill. The goal of this research was to find a way to force these cancer cells to turn back into "bricks" and stop spreading.

The Villain: The "Scissors" (CPSF73)

Inside every cell, there is a complex instruction manual (DNA) that gets copied into a working document (mRNA). Before the cell can read this document to build proteins, it needs to be edited.

Enter CPSF73. Think of CPSF73 as a pair of molecular scissors or an editor. Its job is to cut the mRNA document at a specific spot and add a "tail" (a poly-A tail) to finish the sentence. This tail protects the message and tells the cell how much of the protein to build.

In healthy cells, this editor works perfectly. But in cancer, the editor goes crazy. It starts cutting the documents too early, chopping off important safety warnings (called the 3' UTR).

• The Analogy: Imagine a safety manual that says, "Do not run faster than 50 mph." The cancer editor cuts off that sentence. Now, the cell thinks, "Great! I can run as fast as I want!" This leads to the cell becoming aggressive, mobile, and dangerous.

The Hero: The "Stop Button" (JTE-607)

The researchers tested a drug called JTE-607. Think of this drug as a glove that fits over the molecular scissors (CPSF73), blunting their blades so they can't cut the mRNA documents anymore.

When the researchers put this drug on four different types of cancer cells (breast, liver, and lung), two amazing things happened:

1. The cells stopped multiplying: They couldn't grow as fast.
2. The cells turned back into "bricks": They lost their "jellyfish" mobility and became stationary again. They stopped trying to invade other tissues.

The Mechanism: Lengthening the Safety Net

Why did this happen? When the scissors were blunted, the mRNA documents weren't cut early anymore. Instead, they were allowed to grow longer.

• The Analogy: In the cancer state, the document was a short, 1-page flyer with no safety warnings. When the drug stopped the cutting, the document became a long, detailed manual with all the safety warnings intact.
• Because the document was longer, it had more places for "security guards" (microRNAs and proteins) to grab onto. These guards slowed down the production of dangerous proteins.
• The result? The levels of proteins that drive cancer movement (like AKT2, Zeb1, and Twist) dropped significantly. The cancer cells lost their ability to move and invade.

The "Sniper" Approach: Fixing Just One Problem

The researchers didn't just stop the scissors globally; they wanted to see if they could fix the problem by targeting just one specific gene. They chose AKT2, a gene that acts like a gas pedal for cancer movement.

They used a special tool called an Antisense Morpholino Oligonucleotide (AMO).

• The Analogy: Imagine the mRNA document has a "Stop" sign (a cut site) that the scissors usually hit. The researchers used the AMO to tape over that Stop sign.
• Because the scissors couldn't see the sign, they kept going and cut the document much further down the line. This forced the cell to make the "long version" of the AKT2 manual.
• The Result: Just by taping over that one spot, the cancer cells produced less AKT2 protein, stopped moving, and lost their ability to invade other tissues.

Why This Matters

This study is a game-changer for two reasons:

1. It reveals a new rule: It shows that the length of the genetic message is a major switch that controls whether cancer cells stay put or start spreading.
2. It offers a new strategy: We can fight cancer not just by killing cells, but by re-editing their instructions. By using drugs to blunt the "scissors" or "taping over" specific cut sites, we can force aggressive cancer cells to calm down and stop metastasizing.

In short: The researchers found a way to jam the cancer's editing scissors, forcing the cells to read their full safety manuals again. This turned their "jellyfish" back into "bricks," stopping the spread of the disease.

Technical Summary

1. Problem Statement

Metastasis is the primary cause of cancer-related mortality, driven largely by the Epithelial-Mesenchymal Transition (EMT), a process where epithelial cells lose adhesion and gain migratory mesenchymal properties. A key mechanism in cancer progression is Alternative Polyadenylation (APA), which generates mRNA isoforms with varying 3' untranslated regions (3'UTRs). In many cancers, widespread 3'UTR shortening allows proto-oncogenes to escape miRNA-mediated repression, leading to increased expression of drivers of metastasis.

CPSF73 (Cleavage and Polyadenylation Specificity Factor 73) is the catalytic endonuclease responsible for cleaving pre-mRNA at polyadenylation sites (PAS). High levels of CPSF73 correlate with poor patient prognosis. While previous studies linked CPSF73 inhibition to reduced proliferation, the specific role of CPSF73-mediated APA changes in regulating the EMT process and whether targeting APA could reverse EMT remained poorly understood.

2. Methodology

The study employed a multi-faceted approach combining chemical inhibition, genetic knockdown, global sequencing, and targeted molecular interventions across four cancer cell lines: MDA-MB-231 (Triple-Negative Breast Cancer), HepG2 (Liver), MCF7 (Breast), and A549 (Lung).

• Chemical Inhibition & Genetic Depletion:
  • Cells were treated with JTE-607, a small-molecule inhibitor of CPSF73 catalytic activity, at low (2.5 µM) and high (10 µM) doses.
  • Inducible shRNA-mediated knockdown (KD) of CPSF73 was used in MDA-MB-231 cells to validate chemical inhibition results.
• Phenotypic Assays:
  • Proliferation: Measured via Sulforhodamine B (SRB) assay and IC50 determination.
  • EMT Markers: Western blotting for epithelial (E-cadherin) and mesenchymal (N-cadherin, Vimentin, Zeb1, Twist2, Snail) markers.
  • Invasion: Transwell invasion assays using Matrigel-coated membranes.
• Global Profiling (RNA-Seq):
  • QuantSeq (3' mRNA-Seq): Performed on JTE-607-treated vs. control MDA-MB-231 cells to profile global gene expression and APA usage.
  • Bioinformatics: Differential Gene Expression (DGE) analysis (DESeq2) and APA analysis (polyA_DB pipeline) to calculate Relative Expression Difference (RED) values for 3'UTR lengthening/shortening and intronic PAS usage.
  • Pathway Analysis: Gene Set Enrichment Analysis (GSEA) to identify altered signaling pathways (e.g., Notch, WNT, EMT hallmarks).
• Targeted Validation:
  • RT-qPCR: Validated 3'UTR lengthening in specific genes (e.g., TGFBR1, SMAD4, AKT2) using primers for total vs. long isoforms.
  • Antisense Morpholino Oligonucleotides (AMO): Designed an AMO to specifically block the proximal PAS of AKT2, forcing the use of a distal PAS to mimic the 3'UTR lengthening observed with JTE-607, thereby testing causality.

3. Key Contributions

• Novel Mechanism Discovery: First demonstration that inhibiting CPSF73 not only suppresses proliferation but actively reverses EMT, shifting cancer cells from a mesenchymal to an epithelial state.
• APA-EMT Link: Established a coordinated mechanism where 3'UTR lengthening of specific EMT-related genes leads to their downregulation, thereby suppressing metastasis.
• Therapeutic Strategy: Proposed two distinct therapeutic avenues:
  1. Broad: Chemical inhibition of CPSF73 to globally alter APA and suppress multiple metastatic pathways.
  2. Specific: Use of Antisense Oligonucleotides (ASOs/AMOs) to target specific PASs (e.g., in AKT2) to reverse EMT without global inhibition.

4. Key Results

A. Inhibition of CPSF73 Suppresses Proliferation and Reverses EMT

• Growth Arrest: JTE-607 treatment significantly attenuated proliferation in all four cell lines. This was accompanied by increased expression of the cell cycle inhibitor p21 and decreased MYC protein levels (due to transcriptional readthrough at the MYC PAS).
• EMT Reversal: Treatment with JTE-607 or CPSF73 KD resulted in:
  • Increased E-cadherin (epithelial marker).
  • Decreased Zeb1, Twist2, N-cadherin, and Vimentin (mesenchymal markers).
  • Reduced cell invasion in Transwell assays.

B. Global APA Landscape Changes

• 3'UTR Lengthening: QuantSeq analysis revealed a global shift toward 3'UTR lengthening (Ratio of lengthening to shortening = 2.4).
• Intronic PAS Suppression: There was a significant suppression of intronic polyadenylation events (Suppression/Activation ratio = 1.8).
• Gene Expression Correlation: While 3'UTR APA changes did not strongly correlate with mRNA abundance changes, intronic APA changes showed a significant correlation with gene expression (activation of intronic PASs led to decreased expression).
• Pathway Enrichment: GSEA showed downregulation of Notch and WNT signaling pathways (pro-EMT) and upregulation of Apical Junction and Epithelial Differentiation gene sets.

C. Specific Gene Validation (The "Lengthening" Effect)

• Several key EMT drivers (TGFBR1, SMAD4, TBX2, PAK1, CD44, ERBB2) exhibited 3'UTR lengthening and subsequent protein downregulation upon JTE-607 treatment, despite variable mRNA level changes. This suggests the lengthening introduced regulatory elements (e.g., miRNA/RBP sites) that destabilized the mRNA or inhibited translation.

D. Causal Role of AKT2 APA

• AKT2 was identified as a critical target: It showed significant 3'UTR lengthening (RED = 2.47) and protein downregulation.
• AMO Experiment: Blocking the proximal PAS of AKT2 with an AMO successfully:
  • Shifted the isoform balance toward the long 3'UTR variant.
  • Reduced AKT2 protein levels.
  • Downregulated EMT markers (Snail, N-cadherin, Zeb1).
  • Reduced cell invasion by >50% in MDA-MB-231 cells.
• This confirmed that manipulating APA at a single locus (AKT2) is sufficient to drive partial EMT reversal and inhibit metastasis.

5. Significance

• Therapeutic Potential: The study highlights CPSF73 inhibition as a promising strategy to suppress metastasis by reversing EMT. Unlike traditional kinase inhibitors, this approach targets the fundamental processing machinery of mRNA, potentially affecting multiple oncogenic pathways simultaneously.
• Precision Medicine: The successful use of AMOs to target AKT2 demonstrates that specific APA events can be therapeutically manipulated to reverse malignant phenotypes, offering a more targeted approach than global enzyme inhibition.
• Mechanistic Insight: The findings resolve a gap in understanding how post-transcriptional regulation (APA) directly controls the EMT transition, suggesting that 3'UTR lengthening is a critical "brake" on metastatic drivers in cancer cells.
• Clinical Relevance: Given that high CPSF73 correlates with poor prognosis, these findings support the development of CPSF73 inhibitors (like JTE-607) or APA-targeting ASOs as novel anti-metastatic therapies, potentially effective across diverse cancer types (breast, lung, liver).